Rivaroxaban and apixaban are direct oral anticoagulants (DOACs) targeting Factor Xa. A major clinical advantage over warfarin is their predictable pharmacokinetics. Which specific pharmacological property most contributes to their predictability?

• A DOACs have low inter-individual variability in CYP450 metabolism, are not affected by Vitamin K dietary intake, and have minimal protein binding displacement interactions compared to warfarin's CYP2C9/VKORC1 pharmacogenomic variability ✓
• B DOACs have a longer half-life than warfarin allowing stable steady-state plasma levels
• C DOACs are substrates of renal tubular efflux only, unlike warfarin which is hepatically metabolized
• D DOACs directly inhibit thrombin unlike warfarin which only inhibits cofactors II, VII, IX, X

Explanation

Warfarin is highly unpredictable because: (1) it is metabolized by CYP2C9 (pharmacogenomic polymorphisms in CYP2C9*2/*3 significantly reduce clearance); (2) its target VKORC1 has genetic variants (VKORC1 -1639G>A) affecting sensitivity; (3) many drug interactions displace warfarin from albumin or inhibit/induce CYP2C9; (4) dietary Vitamin K content competes at VKORC1. Rivaroxaban and apixaban have more consistent absorption, limited CYP3A4 metabolism (with a non-metabolized component excreted renally), no interaction with Vitamin K intake, and clinically manageable drug interactions. This allows fixed dosing without routine INR monitoring.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.